Lucid Diagnostics, Inc. (LUCD) Company Revenue

Risks associated with penetrating the oncology diagnostics market via EsoGuard impact the product rollout schedule for Lucid Diagnostics Inc. (LUCD), where the current mark is 0.01. The lack of alternatives for the molecular test provides Lucid Diagnostics Inc. (LUCD) with complete pricing power. Proprietary sampling methods protect the business from competitive pressure. Sales dynamics confirm scaling growth, yet may indicate a limit to operational efficiency.

Lucid Diagnostics Inc. (LUCD): Revenue and Sales Volume from 07/04/2022 to 11/13/2026

Comprehensive metric breakdowns and analytics for Lucid Diagnostics (LUCD)

- market value and analyst target forecast:

Market Chart Lucid Diagnostics, Inc|LUCD - Price Target Chart

- market capitalization details:

Market Value Lucid Diagnostics Inc.|LUCD - Real Price to Acquire Entire Company

- book capitalization information:

Book Value per Share Lucid Diagnostics|LUCD - Book Capitalization|Market Cap to Net Assets Ratio luciddx.com|LUCD - Company Total Assets

- debt obligations and liquidity statistics:

Total Debt to Capital Coefficient Lucid Diagnostics Inc.|LUCD - Long-Term Debt to Capital|Short-Term Debt to Capital Ratio Lucid Diagnostics, Inc.|LUCD - Company Total Debt|Debt to Net Assets Ratio Lucid Diagnostics Inc.|LUCD - Company Long-Term Debts|Company Short-Term Indebtedness Lucid Diagnostics|Interim Coverage Ratio luciddx.com

- net income and valuation ratios data:

LUCD - Net Profit|Projected Future Earnings Lucid Diagnostics Inc.|LUCD - P/E Multiple|Forward Price to Earnings Multiple luciddx.com|LUCD - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Lucid Diagnostics Inc.|LUCD - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months Lucid Diagnostics|LUCD - Earnings per share for the last twelve months|Year-over-year net earnings per share change for the last twelve months luciddx.com|LUCD - Net earnings per share growth this year|Projected earnings per share increase next year Lucid Diagnostics Inc.

- company sales and revenue statistics:

LUCD - Revenue and Sales Volume|Company Future Sales Lucid Diagnostics, Inc|LUCD - P/S Multiple|Forward Price-to-Revenue Multiple Lucid Diagnostics Inc.

General company analysis:Lucid Diagnostics, Inc - LUCD

Manufactured product of Lucid Diagnostics, Inc

Delays in Medicare coverage for EsoGuard tests and marketing expenses are limiting capital inflows for Lucid Diagnostics Inc. (LUCD). Daily trading revenue captures actual cash inflows, confirming the company's compliance with listing requirements. By analyzing the company's current sales levels, investors assess the actual liquidity of the commercial flow. The stability of this line eliminates any illusion of revenue. This price action directly determines the issuer's fundamental value and market capitalization.

Key competitors